Company news

COSCIENS Biopharma Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Aeterna Zentaris Reports Fourth Quarter and Full-Year 2013 Financial and Operating Results

March 20, 2014

Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2013 Financial and Operating Results on March 20, 2014

March 12, 2014

Aeterna Zentaris: Article on Phase 2 Results for Zoptarelin Doxorubicin in Endometrial Cancer Published in the International Journal of Gynecological Cancer

February 4, 2014

Aeterna Zentaris: Presentations on Zoptarelin Doxorubicin and Disorazol Z Conjugates at Upcoming International Symposium on GnRH

February 3, 2014

Aeterna Zentaris Announces Closing of US$13.2 Million Public Offering of Common Shares and Warrants

January 14, 2014

Aeterna Zentaris Announces Pricing of US$13.2 Million Public Offering of Common Shares and Warrants

January 9, 2014

Aeterna Zentaris NDA for Macimorelin Acetate in AGHD Accepted for Filing by the FDA

January 6, 2014

Aeterna Zentaris Appoints Dr. Richard Sachse as Chief Scientific Officer

January 3, 2014

Aeterna Zentaris Announces Closing of US$15.1 Million Public Offering of Common Shares and Warrants

November 25, 2013

Aeterna Zentaris Announces Pricing of US$15.1 Million Public Offering of Common Shares and Warrants

November 20, 2013

Aeterna Zentaris Reports Third Quarter 2013 Financial and Operating Results

November 5, 2013

Aeterna Zentaris Appoints Chief Commercial Officer, Reaffirming New Company Vision

November 1, 2013

Aeterna Zentaris to Announce Third Quarter 2013 Financial and Operating Results on November 5, 2013

October 29, 2013

Aeterna Zentaris Completes Successful Transfer of Cetrotide® Manufacturing Rights to Merck KGaA

October 1, 2013

Aeterna Zentaris Announces Listing Transfer to NASDAQ Capital Market

August 28, 2013

Aeterna Zentaris Reports Second Quarter 2013 Financial and Operating Results

August 8, 2013

Aeterna Zentaris to Present at Upcoming Canaccord Genuity Global Growth Conference in Boston

August 7, 2013

Aeterna Zentaris to Announce Second Quarter 2013 Financial and Operating Results on August 8, 2013

August 1, 2013

Aeterna Zentaris: First Patient Dosed for Phase 3 Registration Trial in Endometrial Cancer with Zoptarelin Doxorubicin (AEZS-108)

July 31, 2013

Aeterna Zentaris Completes $7.8 Million Registered Direct Offering

July 30, 2013

Aeterna Zentaris to Raise US$7.8 Million in Registered Direct Offering

July 25, 2013

Aeterna Zentaris: Encouraging Final Data for Phase 1 Portion of Ongoing Phase 1/2 Trial with Zoptarelin Doxorubicin (AEZS-108) in Prostate Cancer Reported at ASCO

June 3, 2013

Aeterna Zentaris: Posters to be Presented on Phase 1 and Phase 2 Trials with AEZS-108 in Prostate and Breast Cancer at Upcoming ASCO Meeting

May 23, 2013

Aeterna Zentaris Announces "At-the-Market" Issuance Program

May 21, 2013

Aeterna Zentaris Announces Election of Directors at its Annual Meeting of Shareholders

May 8, 2013

Aeterna Zentaris Reports First Quarter 2013 Financial and Operating Results

May 7, 2013

Aeterna Zentaris to Announce First Quarter 2013 Financial and Operating Results on May 7, 2013 and Hold Annual Shareholders Meeting on May 8, 2013

May 1, 2013

Aeterna Zentaris Newly Appointed CEO, David A. Dodd, to Host Introductory Analyst and Investor Conference Call on Thursday, April 25, 2013

April 23, 2013

Aeterna Zentaris Announces Transfer of Manufacturing Rights Related to Cetrotide® to Merck KGaA

April 17, 2013

David A. Dodd Appointed President & Chief Executive Officer of Aeterna Zentaris Inc.

April 15, 2013

Aeterna Zentaris Presents Encouraging Updated Data on its LHRH Receptor-Targeted Disorazol Z Cytotoxic Conjugates at AACR Meeting

April 10, 2013

Aeterna Zentaris to Present Update on its LHRH Receptor-Targeted Disorazol Z Cytotoxic Conjugates at Upcoming AACR Annual Meeting

April 3, 2013

Aeterna Zentaris Reports Fourth Quarter and Full-Year 2012 Financial and Operating Results

March 21, 2013

Aeterna Zentaris to Present at Upcoming Roth 25th Annual OC Growth Stock Conference

March 13, 2013

Aeterna Zentaris to Announce Fourth Quarter and Full Year 2012 Financial and Operating Results on March 21, 2013

March 12, 2013

Aeterna Zentaris: First Patient Treated for Phase 2 Trial with AEZS-108 in Triple-Negative Breast Cancer

February 20, 2013

Aeterna Zentaris Granted Special Protocol Assessment by the FDA for Phase 3 Registration Trial in Endometrial Cancer with AEZS-108

December 28, 2012

Aeterna Zentaris: Final Phase 2 Data Demonstrate Perifosine and Sorafenib Combination Therapy Well Tolerated by Heavily Pretreated Lymphoma Patients

December 11, 2012

Aeterna Zentaris to Present at Oppenheimer 23rd Annual Healthcare Conference in New York

December 4, 2012

Aeterna Zentaris: Final Phase 2 Data for Perifosine in Lymphomas to be Presented at Upcoming ASH Meeting

November 26, 2012

Aeterna Zentaris: Data Demonstrate that Perifosine Combined with Temsirolimus Was Well Tolerated in Phase 1 Trial in Malignant Glioma

November 19, 2012

Aeterna Zentaris Reports Third Quarter 2012 Financial and Operating Results

November 13, 2012

Aeterna Zentaris Announces Initiation of Phase 2 Portion of Phase 1/2 Trial with AEZS-108 in Prostate Cancer

November 12, 2012

Aeterna Zentaris Presents Proof-of-Concept for Disorazol Z Cytotoxic Conjugates, such as AEZS-125, in Ovarian Cancer Mouse Model at ENA Symposium

November 8, 2012

Aeterna Zentaris to Announce Third Quarter 2012 Financial and Operating Results on November 13, 2012

November 7, 2012

Aeterna Zentaris to Present Proof of Concept for Disorazol Z Cytotoxic Conjugates such as AEZS-125 in Ovarian Cancer Mouse Model at Upcoming ENA Symposium

November 1, 2012

Aeterna Zentaris Regains Compliance with NASDAQ $1.00 Minimum Bid Price Rule

October 22, 2012

Aeterna Zentaris: Phase 3 Results for AEZS-130 in AGHD Presented at GRS and IGF Society Congress

October 18, 2012

Aeterna Zentaris Announces Closing of US$16.5 Million Public Offering of Common Shares and Warrants

October 17, 2012

Aeterna Zentaris Announces Pricing of US$16.5 Million Public Offering of Common Shares and Warrants

October 12, 2012

← Newer news releases · Older news releases →

Decks

The 5 newest of 7 decks. Every deck is listed under its year.